James Malone is an endocrinologist and chief medical officer, Bigfoot Biomedical, which can be reached on Facebook, Twitter @bigfootbiomed, LinkedIn, and Instagram.
Dr. Malone retired from Eli Lilly and Company in 2018, where he worked for 21 years in global diabetes research focused on developing new diabetes products, including insulin analogs, GLP-1 receptor agonists, and insulin delivery devices. Before joining Lilly, Jim was in private practice for 12 years as a diabetes specialist in Indianapolis, IN.
Jim graduated from the Indiana University School of Medicine in 1977. His specialty training included a residency in internal medicine at Methodist Hospital in Indianapolis and a clinical fellowship in diabetes and metabolism at the Joslin Diabetes Center in Boston. Following his retirement from Lilly, Jim was an associate clinical professor (adjunct) at Marian University College of Osteopathic Medicine in Indianapolis from 2019-2020 and consulted with several diabetes companies.
James Malone is an endocrinologist and chief medical officer, Bigfoot Biomedical, which can be reached on Facebook, Twitter @bigfootbiomed, LinkedIn, and Instagram.
Dr. Malone retired from Eli Lilly and Company in 2018, where he worked for 21 years in global diabetes research focused on developing new diabetes products, including insulin analogs, GLP-1 receptor agonists, and insulin delivery devices. Before joining Lilly, Jim was in private practice for 12 years as a diabetes specialist in Indianapolis, IN.
Jim graduated from the Indiana University School of Medicine in 1977. His specialty training included a residency in internal medicine at Methodist Hospital in Indianapolis and a clinical fellowship in diabetes and metabolism at the Joslin Diabetes Center in Boston. Following his retirement from Lilly, Jim was an associate clinical professor (adjunct) at Marian University College of Osteopathic Medicine in Indianapolis from 2019-2020 and consulted with several diabetes companies.
Having spent over 30 years of my career in diabetes, first as a practicing diabetologist and later as a diabetes researcher, I’ve met many people with diabetes. And while diabetes care has evolved significantly over my career, I’m amazed to see that daily insulin management is just as complex and manual for many people, particularly those with type 2 diabetes (T2D) — daily insulin management is just as complex and …
Get free updates delivered free to your inbox.
